Pustulotic arthro-osteitis associated with palmoplantar pustulosis

Journal of Dermatology

Volumn 40, Issue 11, 2013, Pages 857-863

  Yamamoto, Toshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

focal infection; palmoplantar pustulosis; pathogenesis; pustulotic arthro osteitis; SAPHO syndrome; Sonozaki syndrome

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; SALAZOSULFAPYRIDINE;

ARTHRALGIA; ARTICLE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HUMAN; OSTEITIS; PATHOPHYSIOLOGY; PROPIONIBACTERIUM ACNES; PUSTULOSIS PALMOPLANTARIS; PUSTULOTIC ARTHRO OSTEITIS; SAPHO SYNDROME; ACQUIRED HYPEROSTOSIS SYNDROME; ADVERSE EFFECTS; ARTHRITIS, PSORIATIC; COMPLICATION; PSORIASIS; TOBACCO USE;

ACQUIRED HYPEROSTOSIS SYNDROME; ARTHRITIS, PSORIATIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSORIASIS; TOBACCO USE;

EID: 84886953550     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12272     Document Type: Article

References (101)

1. Sonozaki H, Kawashima M, Hongo O, et al,. Incidence of arthro-osteitis in patients with pustulosis palmaris et plantaris. Ann Rheum Dis 1981; 40: 554-557.
2. Yamamoto T,. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2009; 23: 1227-1232.
3. Brunasso AMG, Massone C,. Can we really separate palmoplantar pustulosis from psoriasis? J Eur Acad Dermatol Venereol 2010; 24: 619-621.
4. Yamamoto T,. Can we really separate palmoplantar pustulosis from psoriasis? Reply J Eur Acad Dermatol Venereol 2010; 24: 621.
5. De Waal AC, van de Kerkhof PC,. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat 2011; 22: 102-105.
6. Ozawa M, Terui T, Tagami H,. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology 2005; 211: 249-255.
7. Keller M, Spanou Z, Schaerli P, et al,. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 2005; 175: 7678-7686.
8. Eriksson MO, Hagforsen Lundin IP, Michaëlsson G,. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998; 138: 390-398.
9. Murakami M, Ohtake T, Horibe Y, et al,. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 2010; 130: 2010-2016.
10. Hagforsen E, Michaëlsson G, Stridsberg M,. Normal and PPP-affected palmoplantar sweat gland express neuroendocrine markers chromogranins and synaptophysin differently. Arch Dermatol Res 2010; 302: 685-693.
11. Scott DA, Martin M,. Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases. World J Gastroenterol 2006; 12: 7451-7459.
12. D'hoedt D, Bertrand D,. Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin Ther Targets 2009; 13: 395-411.
13. Wang H, Yu M, Ochani M, et al,. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
14. Hagforsen E, Edvinsson M, Nordlind K, Michaëlsson G,. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 2002; 146: 383-391.
15. Kataura A, Tsubota H,. Clinical analyses of focus tonsil and related diseases in Japan. Acta Otolaryngol Suppl 1996; 523: 161-164.
16. Akiyama T, Seishima M, Watanabe H, Nakatani A, Mori S, Kitajima Y,. The relationship of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol 1995; 22: 930-934.
17. Takahara M,. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72: 86-88.
18. Nozawa H, Kishibe K, Takahara M, Harabuchi Y,. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol 2005; 116: 42-53.
19. Murakata H, Harabuchi Y, Kataura A,. Increased interleukin-6, interferon-gamma and tumor necrosis factor-alpha production by tonsillar mononuclear cells stimulated with alpha-streptococci in patients with pustulosis palmaris et plantaris. Acta Otolaryngol 1999; 119: 384-391.
20. Yoshizaki T, Bandoh N, Ueda S, et al,. Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol 2009; 157: 71-82.
21. Sakiyama H, Kobayashi S, Dianzani U, et al,. Possible involvement of T cell co-stimulation in pustulosis palmaris et plantaris via the induction of inducible co-stimulator in chronic focal infections. J Dermatol Sci 2008; 50: 197-207.
22. Tsan M-F, Gao B,. Heat shock protein and innate immunity. Cell Mol Immunol 2004; 1: 274-279.
23. Izaki S, Goto Y, Kaburagi Y, et al,. Antibody production to heat shock proteins with Mr 65 kD (HDP65) in cutaneous inflammation: a possible relation to focal infection. Acta Otolaryngol (Suppl) 1996; 523: 197-200.
24. Seibl R, Birchler T, Loeliger S, et al,. Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 1221-1227.
25. Harper EG, Guo C, Rizzo H, et al,. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129: 2175-2183.
26. Laan M, Cui ZH, Hoshino H, et al,. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162: 2347-2352.
27. Lillis JV, Guo C-S, Lee JJ, Blauvelt A,. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol 2010; 146: 918-919.
28. Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G,. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol 2010; 163: 572-579.
29. Murakami M, Hagforsen E, Morhenn V, et al,. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20: 845-847.
30. Kingo K, MÓ§ssner R, Kõks S, et al,. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol 2007; 156: 646-652.
31. Rudwaleit M, van der Heijde D, Landewé R, et al,. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
32. Chigira M, Maehara S, Nagase M, et al,. Sternocostoclavicular hyperostosis. A report of nineteen cases, with special reference to etiology and treatment. J Bone Joint Surg 1986; 68: 103-112.
33. Yamamoto T,. Increased levels of matrix metalloproteinase-3 in the sera and synovial fluids of patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: report of 2 cases. Rheumatol Int 2013; 33: 1911-1913.
34. Takagi M, Oda J, Tsuzuki N, Sonozaki H,. Palmoplantar pustulotic arthro-osteitis of the peripheral joints with no sternocostoclavicular lesions. Ann Rheum Dis 1992; 51: 558-560.
35. Seno A, Arata J, Matsuura Y, Suemitsu I,. Palmoplantar pustulosis with pustulotic arthroosteitis involving temporal osteomyelitis and meningitis. J Dermatol 2000; 27: 269-272.
36. Hiraiwa T, Rokkaku Y, Yamamoto T,. Palmoplantar pustulosis with arthro-osteitis triggered by recurrent appendeal abscess 5 years after appendectomy. Int J Dermatol 2013 (Epub ahead of print).
37. Kikuchi N, Yamamoto T,. Dental infection as a triggering factor in palmoplantar pustulosis. Acta Derm Venereol 2013 (Epub ahead of print).
38. Yamamoto T,. Triggering role of focal infection in the induction of extra-palmoplantar lesions and pustulotic arthro-osteitis associated with palmoplantar pustulosis. Adv Otorhinolaryngol 2011; 72: 89-92.
39. Yamamoto T, Katayama I, Nishioka K,. Restricted usage of the T-cell receptor Vβ repertoire in tonsillitis in association with palmoplantar pustulosis. Acta Derm Venereol (Stockh) 1998; 78: 161-163.
40. Yamamoto T, Kimura K, Katayama I, Nishioka K,. Successful treatment of severe arthralgia associated with palmoplantar pustulosis with low-dose oral cycloporin A. J Dermatol 1995; 22: 512-514.
41. Vaccaro M, Borgia F, Guarneri F, et al,. Successful treatment of pustulotic arthro-osteitis (Sonozaki syndrome) with systemic cyclosporin. Clin Exp Dermatol 2001; 26: 45-47.
42. Hayama K, Inadomi T, Fujisawa D, Terui T,. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol 2010; 20: 758-762.
43. Edlund E, Johnsson U, Lingren L, et al,. Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis 1988; 47: 809-815.
44. Krishnan V, Bryant HU, MacDougald OA,. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209.
45. Chen G, Deng C, Li Y-P,. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272-288.
46. Schett G, Zwerina J, David JP,. The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 2008; 4: 473-480.
47. Westman M, Engström M, Catrina AI, Lampa J,. Cell specific synovial expression of nicotinic alpha7 acetylcholine receptor in rheumatoid arthritis and psoriatic arthritis. Scand J Immunol 2009; 70: 136-140.
48. van Maanen MA, Stoof SP, van der Zanden EP, et al,. The α7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: a possible role for a key neurotransmitter in synovial inflammation. Arthritis Rheum 2009; 60: 1272-1281.
49. Cooke J,. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci 2007; 80: 2347-2351.
50. Raychaudhuri SP, Raychaudhuri SK,. Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res 2004; 146: 433-437.
51. Seidel MF, Herguijuela M, Forkert R, Otten U,. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010; 40: 109-126.
52. Takahashi T, Yamashita H, Nakamura S, Ishiguro H, Nagatsu T, Kawakami H,. Effects of nerve growth factor and nicotine on the expression of nicotinic acetylcholine receptor subunits in PC12 cells. Neurosci Res 1999; 35: 175-181.
53. Yamamoto T, Ohkubo H, Nishioka K,. Plantar neurofibroma associated with palmoplantar pustulosis. J Am Acad Dermatol 1994; 30: 122-123.
54. Colina M, Govoni M, Orzincolo C, Trotta F,. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperosotosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum 2009; 61: 813-821.
55. Torii H, Nakagawa H, Ishibashi Y,. Osteoarthritis in 84 Japanese patients with palmoplantar pustulosis. J Am Acad Dermatol 1994; 31: 732-735.
56. Boutin RD, Resnick D,. The SAPHO syndrome: an evolving concept for unifying several idiopathic disorders of bone and skin. AJR 1998; 170: 585-591.
57. Perry AL, Lambert PA,. Propionibacterium acnes. Lett Appl Microbiol 2006; 42: 185-188.
58. Kim J, Ochoa M-T, Krutzik SR, et al,. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-1541.
59. Shibata M, Katsuyama M, Onodera T, et al,. Glucocorticoids enhance toll-like receptor 2 expression in human keratinocytes stimulated with propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol 2009; 129: 375-382.
60. Ferguson PJ, Lokuta MA, El-Shanti HI, et al,. Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype. Arthritis Rheum 2008; 58: 3264-3269.
61. Grange PA, Chéreau C, Raingeaud J, et al,. Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin. PLoS Pathog 2009; 5: e1000527.
62. Hurtado-Nedelee M, Chollet-Martin S, Nicaise-Roland P, et al,. Characterization of the immune response in the synovitis, acne, pustulosis, hyperosotosis, osteitis (SAPHO) syndrome. Rheumatology 2008; 47: 1160-1167.
63. Schaeverbeke T, Lequen L, de Barbeyrac B, et al,. Propionibacterium acnes isolated from synovial tissue and fluid in a patient with oligoarthritis associated with acne and pustulosis. Arthritis Rheum 1998; 41: 1889-1893.
64. Kotilainen P, Merilahti-Palo R, Lehtonen OP, et al,. Propionibacterium acnes isolated from sternal osteitis in a patient with SAPHO syndrome. J Rheumatol 1996; 23: 1302-1304.
65. Colina M, Pizzirani C, Khodeir M, et al,. Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology 2010; 49: 1416-1418.
66. O'Doherty CJ, MacIntyre C,. Palmoplantar pustulosis and smoking. Br Med J 1985; 291: 861-864.
67. Hagforsen E, Mustafa A, Lefvert A-K, et al,. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking? Acta Derm Venereol 2002; 82: 341-346.
68. Giménez-Garcia R, Sánchez-Ramõn S, Cuellar-Olmedo LA,. Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol 2003; 17: 276-279.
69. Miot HA, Miot LD, Lopes PS, et al,. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J Eur Acad Dermatol Venereol 2009; 23: 1173-1177.
70. Michaëlsson G, Gustafsson K, Hagforsen E,. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-738.
71. Harel-Meir M, Sherer Y, Shoenfeld Y,. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol 2007; 3: 707-715.
72. Mandal A, Watson J,. Experience with different treatment modules in hidradenitis supprativa: a study of 106 cases. Surgeon 2005; 3: 23-26.
73. Matusiak L, Bieniek A, Szepietowski JC,. Hidradenitis supprativa and associated factors: still unsolved problems. J Am Acad Dermatol 2009; 61: 362-365.
74. Hagforsen E,. The cutaneous non-neuronal cholinergic system and smoking related dermatoses: studies of the psoriasis variant palmoplantar pustulosis. Life Sci 2007; 80: 2227-2234.
75. Johnson GK, Guthmiller JM, Joly S, et al,. Interleukin-1 and interleukin-8 in nicotine- and lipopolysaccharide-exposed gingival keratinocyte cultures. J Periodontal Res 2010; 45: 583-588.
76. Tsuji G, Takahara M, Uchi H, et al,. An environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling pathway. J Dermatol Sci 2011; 62: 42-49.
77. Yamin M, Holbrook EH, Gray ST, et al,. Cigarette smoke combined with Toll-like receptor 3 signaling triggers exaggerated epithelial regulated upon activation, normal T-cell expressed and secreted/CCL5 expression in chronic rhinosinusitis. J Allergy Clin Immunol 2008; 122: 1145-1153.
78. Fatourechi V,. Demystifying autoimmune thyroid disease. Postgrad Med 2000; 107: 127-134.
79. Heymann WR,. Cutaneous manifestations of thyroid disease. J Am Acad Dermatol 1992; 26: 885-902.
80. Ai J, Leonhardt JM, Heymann WR,. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol 2003; 48: 641-659.
81. Tan RSH,. Acute generalized pustular bacterid. Br J Dermatol 1974; 91: 209-215.
82. Auer-Grumbach P, Pfaffenthaler E, Soyer HP,. Pustulosis acuta generalisata is a post-streptococcal disease and is distinct from acute generalized exanthematous pustulosis. Br J Dermatol 1995; 133: 135-139.
83. Eren M, Fabri M, Krieg T, Eming SA,. Pustulosis acuta generalisata with joint involvement in an HLA-A2- and HLA-B-35-positive patient. J Am Acad Dermatol 2008; 58: 1056-1058.
84. Yoshida Y, Nishimura Y, Tanaka T,. A case of pustulosis palmaris et plantaris that began as generalized pustular eruption. J Dermatol 2003; 30: 141-145.
85. Sieper J, Rudwaleit M, Braun J, van der Heijde D,. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum 2002; 46: 319-327.
86. Olivieri I, Salvarani C, Cantini F,. RS3PE syndrome: an overview. Clin Exp Rheumatol 2000; 18 (Suppl 20): S53-S55.
87. Smith EJ, Allantaz F, Bennett L, et al,. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr Genomics 2010; 11: 519-527.
88. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T,. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH): a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66: 409-415.
89. Tlouga BE, Podjasek JO, O'Haver J, et al,. Chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with associated neutrophilic dermatoses: a report of seven cases and review of the literature. Pediatr Dermatol 2009; 26: 497-505.
90. Wagner AD, Andresen J, Jendro MC, et al,. Sustained response to tumor necrosis factor-α-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46: 1965-1968.
91. Olivieri I, Padula A, Ciancio G, et al,. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61: 375-376.
92. Iqbal M, Kolodney MS,. Acne fulminans with synovitis-acne-pustulosis- hyperosotosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005; 52: S118-S120.
93. Ben Abdelghani K, Dran DG, Gottenberg JE, et al,. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 2010; 37: 1699-1704.
94. Zhao Z, Li Y, Li Y, Zhao H, Li H,. Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with review of the relevant published work. J Dermatol 2011; 38: 155-159.
95. Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM,. Treatment of SAPHO with pamidronate. Rheumatology 2002; 41: 1196-1198.
96. Amital H, Applbaum YH, Aamar S, et al,. SAPHO syndrome treated with pamidronate: an open label study of 10 patients. Rheumatology 2004; 43: 658-661.
97. Kerrison C, Davidson JE, Cleary AG, et al,. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology 2004; 43: 1246-1251.
98. Valls-Roc M, Sanmarti M, Salles M, Holgado S, Olive A,. SAPHO syndrome and pamidronate revisited. Rheumatology 2005; 44: 137.
99. Colina M, La Corte R, Trotta F,. Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol 2009; 27: 112-115.
100. Magrey M, Khan MA,. New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Curr Rheumatol Rep 2009; 11: 329-333.
101. Carneiro S, Sampaio-Barros PD,. SAPHO syndrome. Rheum Dis Clin N Am 2013; 39: 401-418.